News
- 16 March 2020News UpdateCOVID-19In light of the ongoing COVID-19 outbreak, we wish to briefly update you......Read more
- 12 December 2019Press ReleaseCergentis launches TLA technology for complete cancer gene mutation sequencingUTRECHT, THE NETHERLANDS - 07:00 CET, December 12, 2019 - Cergentis, a genomics company that develops and commercialises kits and services based on its propriet...Read more
- 1 November 2019News UpdateCergentis appoints new CFOIt is a true pleasure to announce that Jean-Marc Roelandt has joined Cergentis as Chief Financial Officer. Jean-Marc is a senior level executive with more than ...Read more
- 16 September 2019Press ReleaseCergentis appoints new boardUtrecht, The Netherlands - September 16, 2019. Cergentis, a genomics company that develops and commercializes kits and services based on its proprietary Targete...Read more
- 11 September 2019News UpdateCergentis on track with product development of TLA-based targeted complete next generation sequencing on FFPE samples for cancer diagnosticsBy combining proximity ligation with improved targeting strategies, we are able to sequence genes of interest completely, over a large width of 100’s of kilobas...Read more
- 8 September 2019PublicationsPacBio & Cergentis: TLA and Long-Read SequencingPacific Biosciences and Cergentis have presented the combination of TLA and the Pacific Biosciences SMRT sequencing technology...Read more
- 31 August 2019News UpdateNew appnote releasedCergentis released a new application note: "Complete locus sequencing and quality control of targeted genome editing". ...Read more
- 1 August 2019BlogNew laboratory robotsOur new laboratory robots have arrived at our facility. ...Read more
- 9 April 2019News UpdateCergentis releases two new application notes: improving QC in cell & gene therapy manufacturing with TLAOur Targeted Locus Amplification (TLA) technology has unique advantages in the quality control of transgenic and genetically engineered samples. TLA can assess ...Read more